Neutralizing monoclonal antibody in patients with coronavirus disease 2019 : an observational study
© 2022. The Author(s)..
BACKGROUND: Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy.
METHODS: We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome.
RESULTS: In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels.
CONCLUSION: The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
---|---|
Enthalten in: |
Virology journal - 19(2022), 1 vom: 15. Dez., Seite 218 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liao, Xuejiao [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 20.12.2022 Date Revised 24.01.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12985-022-01944-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM350346003 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM350346003 | ||
003 | DE-627 | ||
005 | 20231226044805.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12985-022-01944-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1167.xml |
035 | |a (DE-627)NLM350346003 | ||
035 | |a (NLM)36522677 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liao, Xuejiao |e verfasserin |4 aut | |
245 | 1 | 0 | |a Neutralizing monoclonal antibody in patients with coronavirus disease 2019 |b an observational study |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.12.2022 | ||
500 | |a Date Revised 24.01.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a BACKGROUND: Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy | ||
520 | |a METHODS: We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome | ||
520 | |a RESULTS: In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels | ||
520 | |a CONCLUSION: The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection | ||
650 | 4 | |a Observational Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Antibody therapy | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Clinical manifestation | |
650 | 4 | |a Delta variant | |
650 | 4 | |a SARS-CoV-2 | |
650 | 7 | |a romlusevimab |2 NLM | |
650 | 7 | |a SM01RRU9KK |2 NLM | |
650 | 7 | |a amubarvimab |2 NLM | |
650 | 7 | |a 2AD5KH3SE4 |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Immunoglobulin G |2 NLM | |
700 | 1 | |a Li, Dapeng |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jie |e verfasserin |4 aut | |
700 | 1 | |a Liu, Zhi |e verfasserin |4 aut | |
700 | 1 | |a Ma, Zhenghua |e verfasserin |4 aut | |
700 | 1 | |a Dong, Jingke |e verfasserin |4 aut | |
700 | 1 | |a Yang, Xiangyi |e verfasserin |4 aut | |
700 | 1 | |a Shu, Dan |e verfasserin |4 aut | |
700 | 1 | |a Yuan, Jing |e verfasserin |4 aut | |
700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zheng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Virology journal |d 2004 |g 19(2022), 1 vom: 15. Dez., Seite 218 |w (DE-627)NLM151772509 |x 1743-422X |7 nnns |
773 | 1 | 8 | |g volume:19 |g year:2022 |g number:1 |g day:15 |g month:12 |g pages:218 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12985-022-01944-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 19 |j 2022 |e 1 |b 15 |c 12 |h 218 |